Astrocytic APOE3-Christchurch expression ameliorates brain amyloid-β pathology in 5xFAD mice

May combine two claims.

Homozygosity for APOE3Ch in a PSEN1 p.E280A carrier resulted in markedly reduced tau pathology and delayed dementia onset despite extensive amyloid deposition.

“Homozygosity for APOE3Ch in this individual resulted in markedly reduced tau pathology and delayed dementia onset despite extensive amyloid deposition [3].”

• cites [3] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. sourcePartly supported

  The Abstract reports APOE3 Christchurch homozygosity, unusually high amyloid burden, relatively limited tau burden, and clinical onset decades later than typical PSEN1 E280A carriers. But it proposes, rather than establishes, that APOE3ch caused this resistance; it acknowledges that other factors could have contributed and that the basis for delayed dementia cannot be confirmed. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Mounting evidence from human-based, in vitro, and in vivo studies has linked APOE3Ch to reduction in tau pathology.

“Mounting evidence from human-based, in vitro, and in vivo studies has linked APOE3Ch to reduction in tau pathology [3–7, 24, 26, 41, 42].”

• cites [3] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. sourceSupported
• cites [4] Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread. Cell. 2024;187:428–445.e420. sourceNot checked — no full text of the source
• cites [5] Gunaydin C, Sondhi D, Kaminsky SM, Lephart HC, Leopold PL, Hackett NR, et al. AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer’s disease mice. Mol Ther. 2024;32:4303–18. sourceSupported
• cites [6] Nelson MR, Liu P, Agrawal A, Yip O, Blumenfeld J, Traglia M, et al. The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26:2104–21. sourcePartly supported

  The Main section reports minimal tau burden in a human APOE3-Christchurch homozygote. The Results report reduced phosphorylated tau in cultured human neurons and tauopathy mice carrying homozygous R136S, but those experiments introduced the mutation into APOE4, not APOE3-Christchurch. Thus the paper supports the human observation and related in vitro and in vivo evidence, but not the claim that all three lines of evidence tested APOE3-Christchurch itself. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [7] Tran KM, Kwang NE, Butler CA, Gomez-Arboledas A, Kawauchi S, Mar C, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegener. 2025;20:9. sourcePartly supported

  The Background reports a human APOE3Ch case with relatively low tau-tangle burden, and the Discussion acknowledges studies in humanized mice that found rescue of tau pathology. But this paper's own PS19 mouse results did not show reduced tau pathology—some phosphorylated tau measures increased—and the retrieved passages do not establish the claimed in vitro evidence. No page numbers are provided in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [24] Chen G, Wang M, Zhang Z, Hong DK, Ahn EH, Liu X, et al. ApoE3 R136S binds to Tau and blocks its propagation, suppressing neurodegeneration in mice with Alzheimer’s disease. Neuron. 2025;113:719–736.e715. sourceSupported
• cites [26] Ochiishi T, Kaku M, Kiyosue K, Doi M, Urabe T, Hattori N, et al. New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid beta oligomers. Sci Rep. 2019;9:17368. sourceCould not verify

  The Results section reports increased tau phosphorylation in aged Aβ-GFP transgenic mice, but does not address APOE3Ch or its effect on tau pathology. Searches for APOE3Ch and the Christchurch variant found no passage about either, so this source cannot verify the attributed claim. (LLM, conf=0.75)

  Experimental — accuracy not yet measured
• cites [41] Sun GG, Wang C, Mazzarino RC, Perez-Corredor PA, Davtyan H, Blurton-Jones M, et al. Microglial APOE3 Christchurch protects neurons from Tau pathology in a human iPSC-based model of Alzheimer’s disease. Cell Rep. 2024;43:114982.Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [42] Naguib S, Lopez-Lee C, Torres ER, Lee SI, Zhu J, Zhu D, et al. APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition. bioRxiv. 2025. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Lipid dysregulation is a hallmark of AD.

“lipid dysregulation is a hallmark of AD [34, 35].”

• cites [34] Cao Y, Zhao LW, Chen ZX, Li SH. New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer’s disease. Front Neurosci. 2024;18:1430465.Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [35] He S, Xu Z, Han X. Lipidome disruption in Alzheimer’s disease brain: detection, pathological mechanisms, and therapeutic implications. Mol Neurodegener. 2025;20:11. sourceSupported

May combine two claims.

AD pathology induces ER stress and excessive UPR activation.

“Since AD pathology induces ER stress and excessive UPR activation [28]”

• cites [28] Ajoolabady A, Lindholm D, Ren J, Pratico D. ER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments. Cell Death Dis. 2022;13:706. sourcePartly supported

  The Facts section says Aβ and tau deposition induce ER stress, but distinguishes adaptive UPR in response to mild stress from excessive, maladaptive UPR associated with advanced AD pathology. The claim omits that stage-dependent qualification and implies excessive activation follows AD pathology generally. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Increased PLIN4 expression increases ferroptosis in tumor cells, Leydig cells, and hippocampal neurons.

“emerging data has linked PLIN4 to ferroptosis with increased PLIN4 expression increasing ferroptosis in tumor cells [38], Leydig cells [39], and hippocampal neurons [40].”

• cites [38] Zhao R, Chen Q, Qiao P, Lu Y, Chen X. A signature of four ferroptosis-related genes in laryngeal squamous cell carcinoma. Transl Cancer Res. 2024;13:2938–49. sourcePartly supported

  Citation [38] is attached to the tumor-cell portion of the sentence, not the separately cited Leydig-cell or hippocampal-neuron claims. The Discussion says PLIN4 may promote ferroptosis in a GSH-dependent manner and can be upregulated after treatment with a ferroptosis inducer. It does not establish that increased PLIN4 expression itself increases ferroptosis in tumor cells; the citing sentence presents that causal effect as certain and omits the condition. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [39] Zhang XD, Sun J, Zheng XM, Zhang J, Tan LL, Fan LL, et al. Plin4 exacerbates cadmium-decreased testosterone level via inducing ferroptosis in testicular Leydig cells. Redox Biol. 2024;76:103312.Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [40] Zeng F, Zhou M, Li Q, Hu H, Chen C. Sevoflurane promotes neuronal ferroptosis via upregulation of PLIN4 to modulate the hippo signaling pathway. Neurotoxicology. 2024;105:1–9. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE aggregation in microglia initiates Aβ seeding in 5xFAD mice.

“recent evidence suggest that APOE aggregation in microglia initiates Aβ seeding in 5xFAD mice [18].”

• cites [18] Kaji S, Berghoff SA, Spieth L, Schlaphoff L, Sasmita AO, Vitale S, et al. Apolipoprotein E aggregation in microglia initiates Alzheimer’s disease pathology by seeding beta-amyloidosis. Immunity. 2025;58:263. sourcePartly supported

  The title reproduced in the indexed copy states that APOE aggregation in microglia initiates β-amyloidosis by seeding it. However, the available main text is a correction notice (p. 263), not the study results, and it does not mention 5xFAD mice. That model-specific part of the claim is not supported by our copy. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Aβ oligomers are the most neurotoxic Aβ species, driving synaptic dysfunction, neuronal loss and cognitive decline in AD.

“Evidence suggests that Aβ oligomers are the most neurotoxic Aβ species, driving synaptic dysfunction, neuronal loss and cognitive decline in AD [25–27].”

• cites [25] Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15:349–57. sourceNot checked — no full text of the source
• cites [26] Ochiishi T, Kaku M, Kiyosue K, Doi M, Urabe T, Hattori N, et al. New Alzheimer’s disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid beta oligomers. Sci Rep. 2019;9:17368. sourcePartly supported

  The Introduction links Aβ oligomers to synaptic changes and impaired cognition, and the Discussion reports synaptic dysfunction and memory impairment in the model mice. But the paper does not establish that oligomers are the most neurotoxic of all Aβ species; it compares toxicity among oligomers of different sizes. The Discussion also reports no neuronal cell death in either young or old model mice. Page numbers are unavailable in our copy. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [27] Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med. 2008;14:837–42. sourcePartly supported

  The paper’s Abstract reports that Aβ oligomers from AD brains impaired synaptic plasticity, reduced dendritic spine density, and disrupted learned-behavior memory in rodents; monomers and insoluble plaque cores did not significantly alter synaptic plasticity. It does not establish that oligomers are the most neurotoxic Aβ species overall, or show that they cause neuronal loss or cognitive decline in AD patients. Dendritic spine loss is not neuronal loss. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

The observations could reflect reduced cellular uptake and lysosomal degradation, consistent with impaired receptor binding of APOE3Ch to receptors such as LDLR and HSPGs.

“These observations could also reflect reduced cellular uptake and lysosomal degradation, consistent impaired receptor binding of APOE3Ch to its receptors such as LDLR and HSPGs [3, 16, 17]”

• cites [3] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. sourcePartly supported

  The paper’s Abstract reports reduced LDLR binding by APOE3 Christchurch and its low heparin-binding ability, and notes a possible role for HSPGs in neuronal uptake of extracellular tau. It does not report reduced cellular uptake or lysosomal degradation caused by APOE3 Christchurch; those remain proposed explanations in the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [16] Georgiadou D, Chroni A, Vezeridis A, Zannis VI, Stratikos E. Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia. PLoS One. 2011;6:e27037. sourcePartly supported

  The Introduction identifies apoE3[R136S] as the Christchurch variant and reports 60% reduced LDL-receptor binding for its lipid-bound form. It reports reduced HSPG binding for other apoE3 variants, not Christchurch, and does not address reduced cellular uptake or lysosomal degradation. Those parts of the proposed explanation are not supported by this paper. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [17] Guo JL, Braun D, Fitzgerald GA, Hsieh YT, Rouge L, Litvinchuk A, et al. Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell. 2025;188:187–206.e126. sourcePartly supported

  The Results section on the Christchurch mutation (page unavailable) reports impaired LDLR and heparin binding by ApoE3ch and reduced cellular uptake; the Discussion also identifies impaired HSPG binding. The paper links ApoE uptake to endolysosomal compartments, but these passages do not establish reduced lysosomal degradation of ApoE3ch. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Homozygosity for APOE3Ch was found to be resilient against the onset of a very aggressive form of autosomal AD driven by the PSEN1 p.E280A mutation, despite extensive amyloid deposition.

“homozygosity for this rare APOE3 variant was found to be resilient against the onset of a very aggressive form of autosomal AD case driven by the PSEN1 p.E280A mutation, despite extensive amyloid deposition [3].”

• cites [3] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. sourceSupported

Classified as probably not a substantial claim.

All data were analyzed by two-way ANOVA to adjust for sex differences.

“All data were analyzed by two-way analysis of variance (ANOVA) to adjust for sex differences given prior reports of sex-dependent effects on pathology in the 5xFAD model [13], with a Tukey’s post-hoc test using GraphPad Prism 10.”

• cites [13] Forner S, Kawauchi S, Balderrama-Gutierrez G, Kramar EA, Matheos DP, Phan J, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease. Sci Data. 2021;8:270. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Recent observations support activation of ferroptosis, an iron-dependent form of programmed cell death driven by lipid peroxidation, in AD.

“recent observations support activation of ferroptosis, an iron-dependent form of programmed cell death driven by lipid peroxidation, in AD [36, 37].”

• cites [36] Ma H, Dong Y, Chu Y, Guo Y, Li L. The mechanisms of ferroptosis and its role in alzheimer’s disease. Front Mol Biosci. 2022;9:965064.Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [37] Majernikova N, Marmolejo-Garza A, Salinas CS, Luu MDA, Zhang Y, Trombetta-Lima M, et al. The link between amyloid beta and ferroptosis pathway in Alzheimer’s disease progression. Cell Death Dis. 2024;15:782. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

PLIN4 is up-regulated in MPTP-induced mouse models of Parkinson's disease, with PLIN4 levels resulting in disrupted mitophagy as well as impaired chaperone-mediated autophagy.

“It is up-regulated in MPTP-induced mouse models of Parkinson’s disease (PD), with PLIN4 levels resulting in disrupted mitophagy as well as impaired chaperone-mediated autophagy, a mechanism of protein quality control [31, 32].”

• cites [31] Han X, Liu Y, Dai Y, Xu T, Hu Q, Yi X, et al. Neuronal SH2B1 attenuates apoptosis in an MPTP mouse model of Parkinson’s disease via promoting PLIN4 degradation. Redox Biol. 2022;52:102308.Not matched

  Couldn’t be matched to a paper in Crossref, so it can’t be checked.

• cites [32] Han X, Zhu J, Zhang X, Song Q, Ding J, Lu M, et al. Plin4-Dependent lipid droplets hamper neuronal mitophagy in the MPTP/p-Induced mouse model of Parkinson’s disease. Front Neurosci. 2018;12:397. sourcePartly supported

  The Results section reports increased Plin4 expression in MPTP/p-treated mice and shows that Plin4 knockdown restored mitophagy in MPP+-treated SH-SY5Y cells. It does not report that PLIN4 impairs chaperone-mediated autophagy; the autophagy findings concern mitophagy. No page numbers are available in our copy. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3Ch microglia derived from human iPSC led to resistance to Aβ-induced lipid peroxidation and resulting ferroptosis.

“A recent study demonstrated that APOE3Ch microglia derived from human iPSC led to resistance to Aβ-induced lipid peroxidation and resulting ferroptosis [41].”

• cites [41] Sun GG, Wang C, Mazzarino RC, Perez-Corredor PA, Davtyan H, Blurton-Jones M, et al. Microglial APOE3 Christchurch protects neurons from Tau pathology in a human iPSC-based model of Alzheimer’s disease. Cell Rep. 2024;43:114982. sourceSupported

Probably not a substantial claim: may not pass S1 (asserted), S3 (load-bearing). May combine two claims.

Astrocyte-specific deletion of APOE reduces amyloid pathology and associated toxicity.

“reports of astrocyte-specific deletion of APOE reducing amyloid pathology and associated toxicity [19].”

• cites [19] Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Abeta accumulation and plaque-related pathology in a mouse model of amyloidosis. Mol Neurodegener. 2022;17:13. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous in vitro studies reported decreased Aβ aggregation in the presence of recombinant APOE3Ch compared with APOE3.

“This would align with previous in vitro studies reporting decreased Aβ aggregation in the presence of recombinant APOE3Ch compared with APOE3 [3, 24].”

• cites [3] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25:1680–3. sourceSupported
• cites [24] Chen G, Wang M, Zhang Z, Hong DK, Ahn EH, Liu X, et al. ApoE3 R136S binds to Tau and blocks its propagation, suppressing neurodegeneration in mice with Alzheimer’s disease. Neuron. 2025;113:719–736.e715. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

PLIN4 has been reported to be increased in disease-associated oligodendrocytes in a mouse model of amyotrophic lateral sclerosis.

“PLIN4 has also been reported to be increased in disease-associated oligodendrocytes in a mouse model of amyotrophic lateral sclerosis [33].”

• cites [33] Rezaei A, Kocsis-Jutka V, Gunes ZI, Zeng Q, Kislinger G, Bauernschmitt F, et al. Correction of dysregulated lipid metabolism normalizes gene expression in oligodendrocytes and prolongs lifespan in female poly-GA C9orf72 mice. Nat Commun. 2025;16:3442. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE has been shown to influence Aβ plaque morphology.

“APOE has been shown to influence Aβ plaque morphology.”

• cites [44] Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 1999;96:15233–8. sourceNot checked — no full text of the source
• cites [45] Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2000;97:2892–7. sourceSupported
• cites [46] Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047–58. sourceSupported

Classified as probably not a substantial claim.

Aβ oligomers can induce tau hyperphosphorylation.

“several studies reporting that Aβ oligomers can induce tau hyperphosphorylation [51]”

• cites [51] De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging. 2008;29:1334–47. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Aβ oligomers increase binding and internalization of tau oligomers into synapses, facilitating tau spread.

“increase binding and internalization of tau oligomers into synapses, facilitating tau spread [53].”

• cites [53] Kadamangudi S, Marcatti M, Zhang WR, Fracassi A, Kayed R, Limon A, et al. Amyloid-beta oligomers increase the binding and internalization of tau oligomers in human synapses. Acta Neuropathol. 2024;149:2. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Knockin of APOECh into murine Apoe enhances microglial recruitment to plaques and promoted a DAM phenotype in 5xFAD mice, concurrent with reduced plaque burden and neuritic injury.

“knockin of APOECh into murine Apoe also enhances microglial recruitment to plaques and promoted a DAM phenotype in 5xFAD mice, concurrent with reduced plaque burden and neuritic injury [7].”

• cites [7] Tran KM, Kwang NE, Butler CA, Gomez-Arboledas A, Kawauchi S, Mar C, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegener. 2025;20:9. sourcePartly supported

  The Results sections on spatial proteomics and plaque-induced neuronal damage report more plaque-associated DAMs, lower plaque load, and less neuritic damage in 5xFAD;ApoeCh mice. They do not establish increased microglial recruitment to plaques; overall microglial numbers were reduced. Page numbers are not available in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Reports have shown increased microglial engagement to plaques.

“This observation is in contradiction with reports of increased microglial engagement to plaques [4, 7].”

• cites [4] Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread. Cell. 2024;187:428–445.e420. sourceNot checked — no full text of the source
• cites [7] Tran KM, Kwang NE, Butler CA, Gomez-Arboledas A, Kawauchi S, Mar C, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegener. 2025;20:9. sourceSupported

Classified as probably not a substantial claim.

BACE1 is a marker of dystrophic neurites.

“a marker of dystrophic neurites [48]”

• cites [48] Sadleir KR, Kandalepas PC, Buggia-Prevot V, Nicholson DA, Thinakaran G, Vassar R. Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Abeta generation in Alzheimer’s disease. Acta Neuropathol. 2016;132:235–56. sourceSupported

May combine two claims.

Astrocytic expression of APOE3 and APOE3Ch reduced plaque burden and yielded more compact plaques, with APOE3Ch showing the stronger effect.

“We observed that astrocytic expression of APOE3 and APOE3Ch reduced plaque burden and yielded more compact plaques, as assessed by plaque sphericity [14, 15] and mean X-34 intensity, with APOE3Ch showing the stronger effect.”

• cites [14] Liebmann T, Renier N, Bettayeb K, Greengard P, Tessier-Lavigne M, Flajolet M. Three-Dimensional study of Alzheimer’s disease hallmarks using the iDISCO clearing method. Cell Rep. 2016;16:1138–52. sourceSupported
• cites [15] Ennerfelt H, Frost EL, Shapiro DA, Holliday C, Zengeler KE, Voithofer G, et al. SYK coordinates neuroprotective microglial responses in neurodegenerative disease. Cell. 2022;185:4135–4152.e4122. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The more compact plaques could be due to increased levels of the APOE protein itself, or a combination of APOE levels and differential effects of mouse versus human APOE.

“This could be due to increased levels of the APOE protein itself, or a combination of APOE levels and differential effects of mouse versus human APOE [47].”

• cites [47] Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J Clin Invest. 1999;103:R15–R21. sourcePartly supported

  The Discussion proposes differential effects of mouse and human apo E on early amyloid-β deposition, supporting that part of the proposed explanation. But the Results report similar brain apo E levels in the human- and mouse-apo E groups, and the paper does not link either mechanism to more compact plaques. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE deficiency likely exacerbates neuritic dystrophy around fibrillar plaques in APPPS1ΔE9 mice.

“Nonetheless, APOE deficiency likely exacerbates neuritic dystrophy around fibrillar plaques in APPPS1ΔE9 mice [46].”

• cites [46] Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047–58. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Phosphorylation at threonine 231 is an early marker of AD tau pathology in human CSF.

“which is an early marker of AD tau pathology in human CSF [43].”

• cites [43] Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol. 2021;141:709–24. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

AAVrh.10-mediated APOE2 and APOE2Ch expressions in the central nervous system result in similar suppression of gliosis in APP/PS1 mice with APOE4.

“the AAVrh.10-mediated APOE2 and APOE2Ch expressions in the central nervous system results in a similar suppression of gliosis in APP/PS1 mice with APOE4 [5].”

• cites [5] Gunaydin C, Sondhi D, Kaminsky SM, Lephart HC, Leopold PL, Hackett NR, et al. AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer’s disease mice. Mol Ther. 2024;32:4303–18. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Aβ oligomers mis-localize to dendrites and spines causing neurotoxicity.

“mis-localization to dendrites and spines causing neurotoxicity [52]”

• cites [52] Zempel H, Thies E, Mandelkow E, Mandelkow EM. Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci. 2010;30:11938–50. sourcePartly supported

  The section ‘Aβ oligomers induce missorting of Tau’ reports that Aβ oligomers localize to dendrites, particularly spines, and that exposure causes harmful changes including spine loss. But it identifies Tau—not Aβ oligomers—as the protein that is missorted into dendrites; it does not establish that the oligomers themselves are mislocalized. No page number is available in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Multiple studies have demonstrated that APOECh mutation broadly suppresses gliosis, dampens inflammatory gene expression, and modulates DAM phenotypes in an amyloid and tau-context dependent manner.

“Multiple studies have demonstrated that APOECh mutation broadly suppresses gliosis, dampens inflammatory gene expression, and modulates disease-associated microglial (DAM) phenotypes in an amyloid and tau-context dependent manner [4, 5, 7, 42, 50].”

• cites [4] Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread. Cell. 2024;187:428–445.e420. sourceNot checked — no full text of the source
• cites [5] Gunaydin C, Sondhi D, Kaminsky SM, Lephart HC, Leopold PL, Hackett NR, et al. AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer’s disease mice. Mol Ther. 2024;32:4303–18. sourcePartly supported

  The Results (page unavailable) report reduced microglial and astroglial activation after APOE2-Christchurch treatment in amyloid and tau mouse models, along with altered inflammatory-marker expression. The paper measures markers relevant to glial phenotype, but does not establish the claimed modulation of disease-associated microglial (DAM) phenotypes specifically; its findings are also limited to the tested mouse models. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [7] Tran KM, Kwang NE, Butler CA, Gomez-Arboledas A, Kawauchi S, Mar C, et al. APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology. Mol Neurodegener. 2025;20:9. sourcePartly supported

  The Discussion reports a decreased inflammatory response to tau, and the Conclusions describe opposite microglial responses to amyloid plaques and tauopathy. But the Discussion also reports a brain-wide increase in disease-associated microglia and astrocytes in the amyloid model. Thus, this source supports context-dependent modulation, not a broad suppression of gliosis. Page numbers were not provided. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [42] Naguib S, Lopez-Lee C, Torres ER, Lee SI, Zhu J, Zhu D, et al. APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition. bioRxiv. 2025. sourcePartly supported

  The Supplementary material (page not specified) reports that APOE3-R136S reduced the interferon response to tau pathology and rescued tau-induced microglial activation states. It does not establish broad suppression of gliosis or modulation of disease-associated microglial phenotypes across amyloid and tau contexts. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [50] Quiroz YT, Aguillon D, Aguirre-Acevedo DC, Vasquez D, Zuluaga Y, Baena AY, et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer’s disease. N Engl J Med. 2024;390:2156–64. sourceCould not verify

  The Results (Pathological Findings in Persons with APOE3Ch; page unavailable) describe greater amyloid burden and relatively limited tau burden in four heterozygous carriers, but do not report gliosis, inflammatory gene expression, or disease-associated microglial phenotypes. Searches for those terms and for amyloid- and tau-dependent microglial effects found no passage in the paper’s main text that addresses the attributed claim. (LLM, conf=0.72)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Apoe knockout mice exhibit markedly reduced amyloid deposition and develop diffuse, amorphous plaques.

“Apoe knockout mice exhibit markedly reduced amyloid deposition and develop diffuse, amorphous plaques. [44–46].”

• cites [44] Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, et al. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 1999;96:15233–8. sourceNot checked — no full text of the source
• cites [45] Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci USA. 2000;97:2892–7. sourcePartly supported

  The Results section ('Neuritic Plaque Formation Requires apoE Expression'; page unavailable) describes apoE-knockout APPV717F mice as having more diffuse, largely nonfibrillar Aβ deposits, supporting the plaque description. It says average Aβ deposition was only somewhat lower without apoE and was as extensive as in apoE-expressing mice in some animals, so 'markedly reduced amyloid deposition' overstates the finding for total deposition. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [46] Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215:1047–58. sourcePartly supported

  In “ApoE modifies Aβ deposition,” the paper reports strongly reduced fibrillar amyloid burden, but total Aβ deposition increased in the APP PS1 model and did not significantly change in the APP PS1ΔE9 model. In “ApoE regulates amyloid morphology and conformation,” it describes less compact plaques with wispy fibrils and loosely defined cores, supporting the morphology paraphrase. The unqualified claim of markedly reduced amyloid deposition therefore overstates the finding. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Increased neuritic dystrophy has been shown to facilitate tau spreading in tau pre-formed fibrils injection models.

“Since increased neuritic dystrophy has been shown to facilitate tau spreading in tau pre-formed fibrils injection models [49]”

• cites [49] He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, et al. Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 2018;24:29–38. sourcePartly supported

  The Results section reports that plaque-associated dystrophic neurites facilitate aggregation of injected AD-derived tau and that the resulting aggregates may promote wider tau pathology through secondary seeding. But the same section reports no convincing tau pathology after injection of heparin-induced tau preformed fibrils (PFFs) in the mice tested. The claim therefore applies the AD-tau finding to a PFF-injection condition the paper does not support. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

May combine two claims.

Both APOE3 and APOE3Ch astrocytic expression significantly reduced Aβ deposition in the cortex compared to GFP.

“Histological characterization of amyloid plaque burden using MOAB2 antibody to detect total Aβ species and X-34 to stain amyloid cores confirmed that both APOE3 and APOE3Ch astrocytic expression resulted in significant reduction of Aβ deposition in the cortex compared to GFP (Fig. 3A–C).”

May combine two claims.

Viral expression was astrocyte-specific, with strong co-localization of GFP in GFAP-positive and S100b-positive astrocytes but not in NeuN-positive neurons or IBA1-positive microglia.

“Viral expression was astrocyte-specific, with strong co-localization of GFP in GFAP-positive and S100b-positive astrocytes but not in NeuN-positive neurons or IBA1-positive microglia (Fig. 1B).”

May combine two claims.

Soluble protein levels of mouse APOE were significantly reduced in APOE3 and APOE3Ch groups compared to GFP at 8 months of age, but not 3.5 months of age.

“In addition, soluble protein levels of mouse APOE (mAPOE) were significantly reduced in APOE3 and APOE3Ch groups compared to GFP at 8 months of age, but not 3.5 months of age (Fig. 1D, E, and Supp. Figure 2A–C).”

May combine two claims.

Both astrocytic APOE3 and APOE3Ch expressions reduced insoluble Aβ40 and amyloid burden compared to GFP controls.

“While both astrocytic APOE3 and APOE3Ch expressions reduced insoluble Aβ40 and amyloid burden compared to GFP controls”

May combine two claims.

CD68 positivity showed a trend toward reduction with astrocytic APOE3Ch in the cortex, but no significant differences were observed between the APOE groups.

“While CD68 positivity showed a trend toward reduction with astrocytic APOE3Ch in the cortex, no significant differences were observed between the APOE groups (Fig. 4A, E).”

May combine two claims.

Despite higher soluble human APOE level in cortical lysates in the APOE3Ch group compared to APOE3 group, there was no significant difference in the cortical and hippocampal positivity of HA immunostaining signal between the groups.

“Despite higher soluble human APOE level in the cortical lysates in the APOE3Ch group compared to APOE3 group (Fig. 1D, E), there was no significant difference in the cortical and hippocampal positivity of HA immunostaining signal between the groups (Fig. 4A, B, Supp. Figure 4B, C).”

Probably not a substantial claim: may not pass S3 (load-bearing).

No evident changes in the levels of BiP were detected.

“While we did not detect evident changes in the levels of BiP”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims. The quote only partly states this claim.

Hspa5, Hspb1, and Plin4 were downregulated with astrocytic APOE3Ch compared to APOE3 in RNA-seq.

“Hspa5 coding a key endoplasmic reticulum (ER) stress chaperone binding immunoglobulin protein (BiP) or GRP78, Hspb1 coding heat shock protein family B member 1 (HSP-27), and Plin4 coding perilipin 4 (PLIN4) were downregulated with astrocytic APOE3Ch compared to APOE3.”

Probably not a substantial claim: may not pass S3 (load-bearing).

PLIN4 signal appeared both in discrete puncta consistent with lipid droplets and in a more diffuse or perinuclear distribution.

“with signal appearing both in discrete puncta consistent with lipid droplets and in a more diffuse or perinuclear distribution (Fig. 5K).”

May combine two claims.

There was a decrease in cortical GFAP volume that was statistically significant with APOE3 and trending down with APOE3Ch astrocytic overexpression, compared to GFP.

“There was a decrease in cortical GFAP volume that was statistically significant with APOE3 and trending down with APOE3Ch astrocytic overexpression, compared to GFP (Fig. 4A, C).”

Probably not a substantial claim: may not pass S3 (load-bearing).

PLIN4 immunoreactivity was primarily detected in SOX10-positive oligodendrocytes.

“PLIN4 immunoreactivity was primarily detected in SOX10-positive oligodendrocytes”

May combine two claims.

No significant changes in insoluble Aβ levels or differences in detergent-soluble oAβ were observed across groups in the early amyloid 3.5-month-old cohort.

“No significant changes in insoluble Aβ levels (Supp. Figure 2G, H) or differences in detergent-soluble oAβ (Supp. Figure 2I) were observed across groups in the early amyloid 3.5-month-old cohort.”

May combine two claims.

HA immunostaining partially overlapped with X-34+ plaque cores in both APOE3 and APOE3Ch groups, with no evident difference between the two groups.

“HA immunostaining was partially overlapped with X-34+ plaque cores in both APOE3 and APOE3Ch groups, with no evident difference between the two groups.”

May combine two claims.

Astrocytic APOE3Ch expression shows specific increased plaque sphericity and β-sheet density.

“Astrocytic APOE3Ch expression shows specific increased plaque sphericity and β-sheet density”

Probably not a substantial claim: may not pass S3 (load-bearing).

No significant difference was observed between APOE3 and APOE3Ch groups in the measured protein levels.

“No significant difference was observed between APOE3 and APOE3Ch (Fig. 5I, J).”

Probably not a substantial claim: may not pass S3 (load-bearing).

Most immunostaining of APOE co-localized with HA.

“As the AAV construct codes APOE tagged with HA in the C-terminus, we found that most of the immunostaining of APOE was co-localized with HA (Supp. Figure 4A), consistent with prior reports using this construct [10].”

May combine two claims.

Total cortical IBA1 volume was significantly reduced in APOE3 and APOE3Ch groups compared to GFP controls, without significant differences between the APOE groups.

“In addition, astrocytic APOE expression affected microglial activation, with total cortical IBA1 volume significantly reduced in APOE3 and APOE3Ch groups compared to GFP controls (Fig. 4A, D), without significant differences between the APOE groups.”

May combine two claims.

APOE3Ch resulted in a trending increase in mean X-34 intensity within plaques compared to GFP, with no difference to APOE3.

“APOE3Ch resulted in a trending increase in mean X-34 intensity within plaques compared to GFP, with no difference to APOE3 (Fig. 4F, J).”

May combine two claims.

Astrocytic APOE3Ch expression modulates specific Aβ pools, reduces plaque-associated neuritic damage, and dampens microglial activation even in the presence of endogenous murine Apoe.

“Here, we showed that astrocytic APOE3Ch expression modulates specific Aβ pools, reduces plaque-associated neuritic damage, and dampens microglial activation – even in the presence of endogenous murine Apoe.”

May combine two claims.

Reduced microglial recruitment to plaques or proximity to fibrillar deposits was observed by astrocytic expression of APOE3 and APOE3Ch without differences between them.

“we observed reduced microglial recruitment to plaques or proximity to fibrillar deposits by astrocytic expression of APOE3 and APOE3Ch without differences between them.”

Probably not a substantial claim: may not pass S3 (load-bearing).

We noted a small number of APOE-HA positive cells with neuronal morphology in a subset of animals.

“we noted a small number of APOE-HA positive cells with neuronal morphology in a subset of animals.”

May combine two claims.

APOECh substitution potentially modulates amyloid pathology, tau pathology and propagation, and microglia-related inflammatory pathways.

“These findings collectively suggest that APOECh substitution potentially modulates amyloid pathology, tau pathology and propagation, and microglia-related inflammatory pathways.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE3Ch occurs in the APOE ε3 backbone and has been reported in a PSEN1 p.E280A carrier.

“Of note, the rare APOE R136S Christchurch variant occurs in the APOE ε3 backbone (APOE3Ch) and has been reported in a PSEN1 p.E280A carrier.”

May combine two claims.

Astrocytic APOE3Ch sufficiently attenuates Aβ pathology and related toxicity.

“These findings indicate that astrocytic APOE3Ch sufficiently attenuates Aβ pathology and related toxicity, supporting its potential as a therapeutic modifier for AD.”

• AssumptionRests on an assumption: The 5xFAD mouse model recapitulates human AD amyloid pathology sufficiently to test astrocytic APOE3Ch effects.

Probably not a substantial claim: may not pass S3 (load-bearing).

Recent studies in AD mouse models have demonstrated an effect of APOE3Ch in reducing tau pathology and tau propagation.

“Recent studies in AD mouse models have demonstrated an effect of APOE3Ch in reducing tau pathology and tau propagation, yet its effects on amyloid pathology and related toxicity are not fully understood.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The effect of hAPOE on mAPOE levels may reflect indirect consequences of amyloid pathology context.

“The observation suggests that the effect of hAPOE on mAPOE levels may reflect indirect consequences of amyloid pathology context.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The increased detergent solubility of APOE3Ch suggests potential differences in its biochemical properties.

“The increased detergent solubility of APOE3Ch further suggests potential differences in its biochemical properties.”

May combine two claims.

Astrocytic expression of APOE3Ch leads to increased cortical accumulation compared to APOE3, which is not due to differences in viral delivery or transcriptional regulation.

“Taken together, these data demonstrate that astrocytic expression of APOE3Ch leads to increased cortical accumulation compared to APOE3, which is not due to differences in viral delivery or transcriptional regulation.”

May combine two claims.

The effects of APOE are not dependent on just its presence or absence, but also on its levels and the cellular context.

“These findings suggest that the effects of APOE are not dependent on just its presence or absence, but also on its levels and the cellular context.”

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3Ch may have differences in lipidation status between the two isoforms.

“This could translate into differences in lipidation status between the two isoforms.”

Probably not a substantial claim: may not pass S3 (load-bearing).

APOE3Ch may influence lipid handling in oligodendrocytes.

“suggesting that APOE3Ch may influence lipid handling in oligodendrocytes although further study is necessary.”

• AssumptionRests on an assumption: PLIN4 is a regulator of lipid droplets.

Probably not a substantial claim: may not pass S3 (load-bearing).

Aβ40 is the predominant species deposited in cerebral vessel walls.

“the specific decline of Aβ40, the predominant species deposited in cerebral vessel walls [20]”

• cites [20] Akiyama H, Mori H, Sahara N, Kondo H, Ikeda K, Nishimura T, et al. Variable deposition of amyloid beta-protein (A beta) with the carboxy-terminus that ends at residue valine40 (A beta 40) in the cerebral cortex of patients with Alzheimer’s disease: a double-labeling immunohistochemical study with antibodies specific for A beta 40 and the A beta that ends at residues alanine42/threonine43 (A beta 42). Neurochem Res. 1997;22:1499–506. sourceNot checked — no full text of the source

May combine two claims.

Astrocytic APOE3 and APOE3Ch expressions reduce global gliosis, in particular microgliosis.

“Together, these results indicate that astrocytic APOE3 and APOE3Ch expressions reduce global gliosis, in particular microgliosis”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In the APOE3Ch group, 1 female mouse was prematurely sacrificed because of seizures; 2 male mice presented with hydrocephaly and had to be excluded.

“In the APOE3Ch group, 1 female mouse was prematurely sacrificed because of seizures; 2 male mice presented with hydrocephaly and had to be excluded.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

In the APOE3 group, one female had to be excluded due to absence of genomic APOE and APOE at the transcript level and one male had to be excluded due to mis-genotyping.

“Overall, in the APOE3 group, one female had to be excluded due to absence of genomic APOE and APOE at the transcript level and one male had to be excluded due to mis-genotyping.”

May combine two claims.

The reduction in PLIN4 with APOE3Ch astrocytic expression may reflect decreased lipid peroxidation and potentially lessened activation of ferroptotic pathways in the context of amyloid pathology.

“The reduction in PLIN4 that we observed with APOE3Ch astrocytic expression in particular may reflect decreased lipid peroxidation and potentially lessened activation of ferroptotic pathways in the context of amyloid pathology”

• AssumptionRests on an assumption: PLIN4 is a regulator of lipid droplets.

Probably not a substantial claim: may not pass S3 (load-bearing).

RT-QPCR was performed on extracted genomic DNA to assess variability in AAV delivery within the APOE-expressing groups.

“To assess variability in AAV delivery within the APOE-expressing groups, RT-QPCR was performed on extracted genomic DNA using primers targeting the human APOE transgene”

Probably not a substantial claim: may not pass S3 (load-bearing).

In the APOE3Ch group, one female had to be excluded due to no available tissue for downstream experiments.

“In the APOE3Ch group, one female had to be excluded due to no available tissue for downstream experiments.”

Classified as probably not a substantial claim.

Group differences in Fig. 4 were analyzed using two-way ANOVA with Tukey's multiple comparisons test, adjusting for sex.

“Group differences were analyzed using two-way ANOVA with Tukey’s multiple comparisons test, adjusting for sex.”

Probably not a substantial claim: may not pass S3 (load-bearing).

We did not assess CAA directly.

“therefore we did not assess CAA directly.”

May combine two claims.

Astrocytic APOE expression reduces neuritic damage in the vicinity of fibrillar amyloid plaques, with APOE3Ch showing modestly superior effects.

“These results indicate that astrocytic APOE expression reduces neuritic damage in the vicinity of fibrillar amyloid plaques, with APOE3Ch showing modestly superior effects.”

May combine two claims.

APOE3 appears to promote oligomer-prone aggregation of Aβ compared to APOE3Ch, even while reducing total amyloid deposition.

“APOE3 appears to promote oligomer-prone aggregation of Aβ compared to APOE3Ch, even while reducing total amyloid deposition as shown in both our in vivo and in vitro models.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The specific decline of Aβ40 raises the possibility of effects on vascular amyloid.

“raises the possibility of effects on vascular amyloid.”

Classified as probably not a substantial claim.

TaqMan SNP genotyping assay was used to detect the rs121918393 variant (APOE3Ch) and ensure correct group assignment.

“TaqMan SNP genotyping assay (ThermoFisher assay ID: C__27540615_20) was used to detect the rs121918393 variant (APOE3Ch) and ensure correct group assignment, following the manufacturer’s instructions.”

May combine two claims.

The attenuation of Aβ42 oligomers suggests changes in the APOE3Ch astrocyte secretome or APOE-dependent modulation of Aβ42 assembly.

“suggesting changes in the APOE3Ch astrocyte secretome or APOE-dependent modulation of Aβ42 assembly (Fig. 6E–H).”

May combine two claims.

APOE3Ch has better post-transcriptional stabilization or slower turnover and clearance than APOE3.

“These observations suggest that APOE3Ch has better post-transcriptional stabilization or slower turnover and clearance than APOE3.”

May combine two claims.

APOE3Ch promotes a form of plaque compaction that is less damaging to surrounding neurites, potentially by sequestering oligomeric Aβ species and dampening inflammatory and stress-related pathways.

“These results suggest that APOE3Ch promotes a form of plaque compaction that is less damaging to surrounding neurites, potentially by sequestering oligomeric Aβ species and dampening inflammatory and stress-related pathways, as indicated by our transcriptomic analyses.”

May combine two claims.

Astrocytic APOE3Ch can shift Aβ species but does not fully recapitulate the microglial phenotype observed in knockin mouse models, pointing to a potential role for microglia-derived APOECh or a cell-autonomous effect of APOECh on microglial response to Aβ.

“While astrocytic APOE3Ch can shift Aβ species, it does not fully recapitulate the microglial phenotype observed in the knockin mouse models, pointing to a potential role for microglia-derived APOECh or a cell-autonomous effect of APOECh on microglial response to Aβ.”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

Our findings expand upon recent reports characterizing APOE3Ch as a protective variant associated with familial AD cases carrying PSEN1.

“Altogether, our findings expand upon recent reports characterizing APOE3Ch as a protective variant associated with familial AD cases carrying PSEN1.”

Probably not a substantial claim: may not pass S2 (checkable).

Our results underscore the need for cell-type-specific interrogation of APOE biology.

“our results further underscore the need for cell-type-specific interrogation of APOE biology.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The sparse APOE-HA expression in neuronal morphology likely reflects minor leakiness or variability in injection depth near the ventricular zone.

“This sparse expression likely reflects minor leakiness or variability in injection depth near the ventricular zone.”

• AssumptionRests on an assumption: AAV8 has some degree of promoter-independent leakiness.

May combine two claims.

Analysis at 8 months of age captures the 5xFAD model at an advanced stage of pathology, which may limit detection of early or more dynamic APOE effects on plaque seeding or glial transitions.

“our analysis at 8 months of age captures the 5xFAD model at an advanced stage of pathology, which may limit detection of early or more dynamic APOE effects on plaque seeding or glial transitions.”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

APOE3Ch knockin led to overall decrease in both astrocytosis and microglial activation and increased CD68-positive microglial clustering compared with APOE3 knockin in APP/PS1 mice.

“APOE3Ch knockin led to overall decrease in both astrocytosis and microglial activation and, in parallel, increased CD68-positive microglial clustering compared with APOE3 knockin in APP/PS1 mice [4].”

• cites [4] Chen Y, Song S, Parhizkar S, Lord J, Zhu Y, Strickland MR, et al. APOE3ch alters microglial response and suppresses Abeta-induced tau seeding and spread. Cell. 2024;187:428–445.e420. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Previous reports have highlighted structural differences between astrocytic and microglia derived APOE particles.

“previous reports have highlighted structural differences between astrocytic and microglia derived APOE particles [54]”

• cites [54] Wang N, Cai L, Pei X, Lin Z, Huang L, Liang C, et al. Microglial apolipoprotein E particles contribute to neuronal senescence and synaptotoxicity. iScience. 2024;27:110006. sourceNot checked yet

  Checked before — its earlier verdict is held back until a new check runs.